Trial · NCT03032172
Results by group469
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 469
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Adverse Events (AEs) | RO6885247 | 12 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Nusinersen | 76 | Participants | ||
| Number of Participants With Adverse Events (AEs) | Olesoxime | 70 | Participants | ||
| Number of Participants With Adverse Events (AEs) | AVXS-101 | 14 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | RO6885247 | 0 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | Nusinersen | 1 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | Olesoxime | 0 | Participants | ||
| Number of Participants Who Discontinued Treatment Due to AEs | AVXS-101 | 0 | Participants | ||
| Number of Participants With Shift in Puberty Status From Baseline | RO6885247 | Baseline Status Normal: Week 52 Status Normal | 0 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Nusinersen | Baseline Status Normal: Week 52 Status Normal | 0 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Olesoxime | Baseline Status Normal: Week 52 Status Normal | 3 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | RO6885247 | Baseline Status Normal: Week 52 Status Missing | 4 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Nusinersen | Baseline Status Normal: Week 52 Status Missing | 9 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Olesoxime | Baseline Status Normal: Week 52 Status Missing | 27 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | RO6885247 | Baseline Status Delayed: Week 52 Status Normal | 0 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Nusinersen | Baseline Status Delayed: Week 52 Status Normal | 0 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Olesoxime | Baseline Status Delayed: Week 52 Status Normal | 1 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | RO6885247 | Baseline Status Missing: Week 52 Status Missing | 0 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Nusinersen | Baseline Status Missing: Week 52 Status Missing | 1 | Participants | |
| Number of Participants With Shift in Puberty Status From Baseline | Olesoxime | Baseline Status Missing: Week 52 Status Missing | 0 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03032172/results